Eden vs Hers: Compounded Pharmacy and Subscription Telehealth

Comparing Eden and Hers means weighing a compounded-pharmacy service against a large consumer subscription brand. This PlexusDx Education Hub review contrasts how each is built, how transparent the pricing is, and the metabolic layer both skip. Browse the Peptides & GLP-1 hub.

Full head-to-head: PlexusDx vs Eden →

Editorial independence: PlexusDx has no commercial relationship with Hers, Eden, or their parent companies, and this review carries no affiliate links or compensation.

As of July 2026 the telehealth GLP-1 market holds dozens of options. This piece stays with the two named here and where their models diverge.

What Hers brings to weight management

Hers (part of Hims & Hers Health) is a broad subscription telehealth brand with weight management as one of several categories. Its GLP-1 track typically includes a virtual evaluation, a provider-issued prescription, and either brand-name FDA-approved dispensing or compounded semaglutide and tirzepatide through licensed pathways. See Hers's weight-loss page for current details.

What Eden brings to weight management

Eden is a more tightly focused telehealth-plus-compounded-pharmacy service. It dispenses injectable compounded semaglutide and tirzepatide, bills monthly only, and does not charge until a provider approves the prescription. Its structure and offerings live on Eden's official website.

Pricing transparency, side by side

Eden is unusually specific: it advertises $99/month for compounded semaglutide and $199/month for tirzepatide, medication only, but a required Eden Membership ($99/month, disclosed in its own footnote) brings the true all-in cost to $198/month for semaglutide and $298/month for tirzepatide, and it offers a money-back warranty tied to losing 10% of body weight in six months. Eden figures verified at checkout, July 2026. Hers publishes its weight-loss pricing on its own site, where rates vary by medication and plan, so verify current Hers pricing on its official page before deciding.

Where PlexusDx protocols fit

For comparison, PlexusDx runs month-to-month at $189 for Semaglutide Injection and $289 for Tirzepatide Injection, with Semaglutide Oral at $289/month and Tirzepatide Oral at $349/month. A broad subscription brand, a focused compounded service, and a genetics-led protocol each frame the same category differently. None of the three is interchangeable, and the format and billing terms you prefer often narrow the choice faster than the monthly price alone does.

The evidence follows the molecule

Whichever brand prescribes, the pharmacology is the compound's. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide were studied in STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Effect sizes vary by compound, dose, and population, and no subscription tier or membership changes how the underlying molecule behaves once it is prescribed.

The inherited factor neither program reads

Neither Hers nor Eden measures the genetic terrain a GLP-1 compound acts on. TCF7L2, tied to glucose homeostasis and GLP-1 secretion, and FTO, the fat-mass and obesity-associated gene, describe that biology as pathway-level context rather than a response prediction. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, sitting alongside the Weight Management Protocols so the profile and the plan are read together.

Not affiliated: PlexusDx is independent of both Hers and Eden and has no commercial relationship with the companies reviewed above.

Related reading on PlexusDx: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers or Eden and offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols for semaglutide and tirzepatide, or begin upstream with the Precision Peptide Genetic Test to map your GLP-1 pathway before you commit.

Frequently Asked Questions

Is Hers or Eden the better fit for GLP-1 weight management?

Neither is objectively better. Hers offers the breadth of a large subscription brand, while Eden is a focused compounded service with unusually specific pricing. The right fit depends on whether you value platform breadth or pricing clarity, plus cost and format preferences. Review each brand's own disclosures.

How transparent is each program's pricing?

Eden publishes specific numbers, including a headline price plus a required membership that lifts the all-in cost to $198 or $298 per month (verified July 2026). Hers publishes its weight-loss pricing on its own site, where rates vary by medication and plan. Confirm current figures directly before committing.

Does the subscription model change the medication?

No. Subscription structure affects billing and onboarding, not pharmacology. The compound prescribed, a GLP-1 receptor agonist or a GIP/GLP-1 dual agonist, behaves the same through any legitimate program. The platform provides access; the molecule drives the mechanism.

What does the Precision Peptide Genetic Test add here?

It works upstream of both programs. Rather than predicting response to a Hers or Eden prescription, it reads pathway-level variants such as TCF7L2 and FTO that describe your baseline GLP-1 biology, context that holds regardless of which service ends up writing the prescription.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education